30 closest matches · ranked by relevance
Scleroderma · Interstitial Lung Disease
Primary: Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value — 66.52; 66.52; 66.22; 67.03 FVC %-pred — p=0.24
Rheumatologic Disease
Primary: Flow Mediated Dilatation (FMD)-Diameter of Artery — 3.79; 3.78 mm
Scleroderma
Primary: Improvement in the Modified Rodnan Skin Score. — 46.75 percent improvement from baseline
SYSTEMIC SCLERODERMA
Primary: Time to Treatment Failure — 0; 8 participants
Scleroderma · Systemic Sclerosis · Diffuse Scleroderma
Primary: Change in 2- Gene Biomarker — -2.67; 0.42 2- gene biomarkers score
Scleroderma, Systemic
Primary: Percent Change in Modified Rodnan Skin Score at 6 Months Compared to Baseline — -32 percentage of change in MRSS — p=0.005
Systemic Sclerosis
Primary: Change in Modified Rodnan Skin Score (MRSS) — -10; -3.0 units on a scale
Lung Diseases · Pulmonary Fibrosis · Systemic Scleroderma
Primary: Forced Vital Capacity — 66.6; 65.6 % of predicted
Scleroderma, Diffuse · Scleroderma, Systemic
Primary: Change in Modified Rodnan Skin Score — -8.6; -2.3 MRSS score
Systemic Sclerosis · Scleroderma
Primary: The Benefit That an Antifibrotic Agent and Ambrisentan Combination Have on the Cutaneous Involvement of Patients With Early Diffuse Systemic Sclerosis by Utilizing the…
Systemic Sclerosis
Primary: Change From Baseline in Modified Rodnan Skin Score to Week 24 — -2.45; -4.76 score on a scale — p=0.0291
Scleroderma, Systemic
Primary: Change From Baseline in Modified Rodnan Skin Score (mRSS) to Week 52 — -2.088; -0.769 score on a scale — p=0.0815
Systemic Scleroderma
Primary: EFS of Patients Undergoing Transplant — 15 participants
Scleroderma, Systemic · Scleroderma, Diffuse · Scleroderma, Limited
Primary: Digital Skin Microvascular Blood Flow Measured by Laser Doppler Imaging (LDI) Before Cold Stimulus — 260.0; 246.3 perfusion units
Sclerosis, Systemic
Primary: Change From Baseline in Modified Rodnan Skin Score (mRSS) at Week 24 — -1.22; -3.92 unit on a scale — p=0.0915
Systemic Sclerosis-Associated PAH
Primary: Change From Baseline in Distance Walked During a Six Minute Walk Test — 23.6; 0.5 Meters — p=0.12
Systemic Sclerosis
Primary: Change in Modified Rodnan Skin Score (mRSS) During Double-blind Period — -4.41; -6.14 Units on a scale — p=0.0983
Scleroderma
Primary: Mean Skin Stiffness — 2.68; 2.07; 2.23; 2.27 meters per second — p=0.005
Scleroderma, Systemic
Primary: Main Study: Change From Baseline in Modified Rodnan Skin Score (mRSS) at Week 24 — -9.5; 3.1 Score on a scale — p=< 0.001
n Ulcer · Scleroderma, Systemic
Primary: New Digital Ulcers (DU) 4 Weeks Prior to Week 24 — 0.06 new digital ulcers
Systemic Sclerosis
Primary: Improvement in the Modified Rodnan Skin Score — -6.6 units on a scale
Scleroderma
Primary: Cochin Hand Functional Scale — 19.24 units on a scale
Systemic Sclerosis
Primary: Change From Baseline in Modified Rodnan Total Skin Thickness Score (Total mRSS) at Week 24 — -9.5 scores on scale
Scleroderma, Systemic
Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks — -93.3; -52.4 millilitre (mL)/year (yr) — p=0.0350
Systemic Sclerosis · Scleroderma
Primary: Number of Participants Who Experience Grade 3 or Higher Adverse Events That Occur at or Before Week 24 — 0; 0 Participants
Scleroderma, Systemic · Interstitial Lung Disease
Primary: Percent Predicted Forced Vital Capacity (FVC-%) — 2.24; 2.09 percent predicted — p=0.9326
Diffuse Cutaneous Systemic Sclerosis
Primary: Proportion of Participants With at Least One Adverse Events (AEs) or Serious AEs (SAEs) in 1 Year — 35; 40 Participants
Systemic Scleroderma · Severe Systemic Sclerosis
Primary: Event-free Survival (EFS) — 1 Participants
Scleroderma, Systemic
Primary: Mean Change From Baseline in Forced Vital Capacity (FVC) — 0.1786 Liters — p=0.026
Scleroderma
Primary: Change in Managing Symptoms Scale on the PROMIS® Self-efficacy Short Form 8 — 0.35; 0.94; 0.50; 1.49 units on a scale — p=0.87